Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.
PRX 00023
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
To address the development of early anxiety disorders across the lifespan, the High USV line of rats was bred based on rates of… Expand
2008
2008
PRX-00023, a serotonin 1A receptor agonist, was designed to provide high potency and selectivity for its target. To assess the… Expand
2008
2008
BACKGROUND
The serotonin 1A (5-hydroxytryptamine 1A [5-HT1A]) receptor likely plays a critical role in anxiety pathophysiology… Expand
2007
2007
PRX‐00023 is a novel, nonazapirone 5‐HT1A agonist in clinical development for treatment of affective disorders. The objectives of… Expand
2007
2007
: EPIX Pharmaceuticals Inc (formerly Predix Pharmaceuticals Inc) is developing PRX-00023, an oral aryl piperazine 5-HT1A agonist… Expand
Review
2007
Review
2007
EPIX Pharmaceuticals Inc (formerly Predix Pharmaceuticals Inc) is developing PRX-00023, an oral aryl piperazine 5-HT1A agonist… Expand
Highly Cited
2006
Highly Cited
2006
We report the discovery of a novel, potent, and selective amidosulfonamide nonazapirone 5-HT1A agonist for the treatment of… Expand
2006
2006
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the… Expand
2006
2006
To evaluate single and multiple dose pharmacokinetics of PRX‐00023, a novel non‐azapirone 5HT1A agonist in healthy subjects.